Hims & Hers Expands into Europe with ZAVA Acquisition

Hims & Hers Health Inc. (NYSE:HIMS) is one of the best NYSE stocks to buy for long term investment. On June 3, Hims & Hers Health announced its agreement to acquire ZAVA, which is a leading European digital health platform. The acquisition will expand Hims & Hers’ international presence.

In the upcoming quarters, Hims & Hers plans to establish its own branded presence in European markets by using ZAVA’s robust platform. ZAVA currently serves over 1.3 million active customers and conducted ~2.3 million consultations in 2024 across the UK, Germany, France, and Ireland.

Hims & Hers Expands into Europe with ZAVA Acquisition

A nurse in a telehealth platform talking with a patient on video call for consultation.

Hims & Hers intends to introduce a new dimension of personalized digital health in Europe and offer tailored care across dermatology, weight loss, sexual health, and mental health. The expansion will include access to British, German, and French healthcare providers who will deliver services in local languages to ensure a localized experience. While specific offerings and their rollout will be announced in the coming months, the deal is expected to commence by 2026.

Hims & Hers Health Inc. (NYSE:HIMS) is a telehealth platform that connects consumers to licensed healthcare professionals in the US, the UK, and internationally.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.